Get the Stockscreener App
7.03
1.44%
0.10
Pre-market:
7.06
0.03
+0.43%
Biocryst Pharmaceuticals Inc stock is traded at $7.03, with a volume of 3.57M.
It is up +1.44% in the last 24 hours and up +1.44% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$6.93
Open:
$7.04
24h Volume:
3.57M
Relative Volume:
0.80
Market Cap:
$1.48B
Revenue:
$557.51M
Net Income/Loss:
$-35.71M
P/E Ratio:
-39.06
EPS:
-0.18
Net Cash Flow:
$15.50M
1W Performance:
+1.88%
1M Performance:
+1.44%
6M Performance:
-31.95%
1Y Performance:
-3.70%
1-Day Range:
$6.89
$7.09
1-Week Range:
$6.73
$7.205
52-Week Range:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.03 | 1.46B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Resumed | TD Cowen | Buy |
| Oct-01-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
Biotech Stocks Facing FDA Decision In December 2025 - RTTNews
Why BioCryst (BCRX) Might be Well Poised for a Surge - sharewise.com
BioCryst to Present at Morgan Stanley Global Healthcare Conference - AOL.com
Will BioCryst Pharmaceuticals Inc. stock return to pre crisis levelsMarket Sentiment Review & Free High Return Stock Watch Alerts - newser.com
Why BioCryst Pharmaceuticals Inc. stock could benefit from AI revolutionJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - newser.com
BioCryst at Jefferies Conference: Strategic Growth and Acquisitions By Investing.com - Investing.com Canada
BCRX: ORLADEYO growth, Astria acquisition, and Nevenabart launch drive profitability and pipeline momentum - TradingView
Why retail investors pile into BioCryst Pharmaceuticals Inc. stock2025 Market Outlook & Daily Stock Momentum Reports - newser.com
Will BioCryst Pharmaceuticals Inc. stock attract ESG investors2025 Top Decliners & Safe Swing Trade Setups - newser.com
Can BioCryst Pharmaceuticals Inc. stock deliver consistent earnings growth2025 Valuation Update & AI Powered Market Trend Analysis - newser.com
Is BioCryst Pharmaceuticals Inc. stock ready for a breakoutGlobal Markets & Weekly Momentum Picks - newser.com
BioCryst Pharmaceuticals Inc.’s volatility index tracking explainedPortfolio Value Report & Real-Time Volume Analysis Alerts - newser.com
Astria Therapeutics Reports Q3 2025 Results and BioCryst Acquisition - TipRanks
Why Analysts Say the BioCryst Story Is Changing After Astria Therapeutics Acquisition - Yahoo Finance
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - MarketScreener
Is BioCryst Pharmaceuticals Inc. stock bottoming out2025 Analyst Calls & Daily Technical Forecast Reports - newser.com
Will BioCryst Pharmaceuticals Inc. stock maintain growth storyBull Run & Growth-Oriented Investment Plans - newser.com
Trading the Move, Not the Narrative: (BCRX) Edition - news.stocktradersdaily.com
Is BioCryst’s Surging ORLADEYO Sales and Astria Deal Reshaping the Investment Case for BCRX? - Sahm
BioCryst Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - 富途牛牛
Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st
BioCryst’s ORLADEYO shows sustained attack reduction in pediatric HAE By Investing.com - Investing.com South Africa
BioCryst’s ORLADEYO shows sustained attack reduction in pediatric HAE - Investing.com
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat) - GlobeNewswire
Is BioCryst Pharmaceuticals Inc. stock ready for breakoutEarnings Risk Summary & Weekly High Potential Alerts - Fundação Cultural do Pará
BioCryst Pharmaceuticals Shines in Q3 Earnings Call - MSN
Can BioCryst Pharmaceuticals Inc. stock outperform in 2025 bull market2025 Breakouts & Breakdowns & Weekly High Return Forecasts - Fundação Cultural do Pará
What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackPortfolio Profit Report & Real-Time Buy Zone Alerts - newser.com
When is the best time to exit BioCryst Pharmaceuticals Inc.2025 Major Catalysts & Pattern Based Trade Signal System - newser.com
Citizens Maintains BioCryst Pharmaceuticals (BCRX) Market Outperform Recommendation - Nasdaq
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.17%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):